Companies in #Neuroscience

Biogen is a leading global biotechnology company that discovers, develops, and delivers innovative therapies for serious neurological and neurodegenerative diseases. Its portfolio includes medicines for multiple sclerosis, spinal muscular atrophy, Alzheimer's disease, and rare diseases, with a growing late-stage neurology pipeline and recent expansion into rare diseases through the Reata Pharmaceuticals acquisition.

Genentech, a member of the Roche Group, is a leading biotechnology company pioneering breakthrough medicines for serious diseases. With a 40+ year history of biotech innovation, Genentech develops therapeutics across oncology, immunology, neuroscience, ophthalmology, and infectious diseases, and is currently undergoing a strategic R&D restructuring in 2026.

Ipsen is a global specialty biopharmaceutical company focused on oncology, rare disease, and neuroscience, with a portfolio of in-market products including Dysport (botulinum toxin), Somatuline (lanreotide), and Onivyde (irinotecan). The company is advancing a refreshed R&D pipeline in 2026 with multiple Phase 3 readouts planned, alongside a new wave of partnership-led discovery deals.

Slate Medicines is a clinical-stage biotechnology company developing anti-PACAP therapeutics for migraine and headache disorders. The company launched in 2026 with a $130M Series A to advance its lead program SLTE-1009 and other PACAP-pathway candidates, joining a competitive class of next-generation migraine developers seeking to challenge the CGRP inhibitor standard of care.